Potential model of HMQ1611 inhibiting breast cancer cell proliferation

Slides:

Advertisements

Similar presentations

Estrogen & Estrogen Receptor

Advertisements

Figure 1. Resistance mechanism against first generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI). (A) Mutations in the EGFR.

Odds ratios for change in PD from earliest mammogram within levels of earliest PD. No evidence for an interaction of earliest PD and change in PD on breast.

Targeting the PARP DNA repair pathway enhanced cytotoxicity induced by chemotherapy. Targeting the PARP DNA repair pathway enhanced cytotoxicity induced.

KG-501 suppresses NSCLC/IL-1β CM–induced migration of HUVECs by regulating IL-1β–induced CXC chemokine gene expression in NSCLC cells. KG-501 suppresses.

CDK2 is highly expressed in colon cancer cells and curcumin selectively suppresses HCT116 cell proliferation. CDK2 is highly expressed in colon cancer.

سرطان الثدي Breast Cancer

Figure 1 Cellular processes involved in cancer development

Inhibition of PDGFR-β downstream signaling events by flavones.

Fig. 2. Effects of AZD4785 on proliferation and MAPK pathway signaling in KRAS mutant and wild-type cancer cells in vitro. Effects of AZD4785 on proliferation.

MAPK pathway inhibitors.

Figure 4 Possible combination therapies CDK4/6 inhibitors

Figure 1 A schematic representation of the HER2 signalling pathway

Reduction of Sca-1 increases PPARγ expression.

Cetuximab treatment increases IFNγ receptor 1 expression.

Activated membrane signaling promotes survival in response to radiation. Activated membrane signaling promotes survival in response to radiation. Radiation.

The p53 pathway is involved in the inhibition of cell proliferation observed in 15-LOX-1-overexpressing cells. The p53 pathway is involved in the inhibition.

Friends with Benefits: Microenvironmental NRG1β and HGF Mediate HER2-Targeted Resistance in L-HER2+ and HER2E Breast Cancer Sarah B. Crist, Cyrus M.

Schematic representation of signaling pathways modulated by PKD1 in cancer. Schematic representation of signaling pathways modulated by PKD1 in cancer.

Signaling by Ras/Raf/ERK in the regulation of β-cell proliferation.

Model for the regulation of HIPK2 activity and p53 phosphorylations by the ATM pathway. Model for the regulation of HIPK2 activity and p53 phosphorylations.

Thiocolchicoside suppresses cell proliferation and colony formation of various cancer cell lines. Thiocolchicoside suppresses cell proliferation and colony.

eNOS regulated IR-induced NO generation and EGFR signal activation.

Signalling pathways and involved entities that are unravelling experimental therapeutic targets for TNBC. Depicted molecular landscape of TNBC confers.

All Roads Lead to the Ribosome

Lesley-Ann Martin, Mitch Dowsett Cancer Cell

Effect of the PD-1–B7-H1 interaction on cell proliferation potential and drug sensitivity in MOSTI-1 cells. Effect of the PD-1–B7-H1 interaction on cell.

Dietary plant extracts inhibit NF-κB activation in vitro.

Treatment effects of fenretinide (4-HPR, 5 μmol/L), 2-ME (2

Oncogenic indel hotspots.

Imatinib mesylate inhibits PDGF-mediated ERK and Akt activation.

Down-regulation of the erbB-2 receptor by trastuzumab decreases Akt kinase activation but not MAPK activation. Down-regulation of the erbB-2 receptor by.

Matriptase-2 inhibited breast tumor development in vivo.

The effects of IAA and glycyrrhizin (Gc) on proliferation and cell-cycle distribution. The effects of IAA and glycyrrhizin (Gc) on proliferation and cell-cycle.

MiR-200c is a PI3K–AKT signaling pathway regulator in CRC

The effect of IAA and glycyrrhizin (Gc) on growth of human melanoma cells. The effect of IAA and glycyrrhizin (Gc) on growth of human melanoma cells. A,

Specific cytotoxicity of DTEGF13.

Immunohistochemistry for phosphorylated (S235) S6 ribosomal protein and quantitation of Ki67 labeling indices in vehicle- and WAY –treated Eker (Tsc2+/−)

Knockdown of PKM2 suppressed TPA-induced skin cell transformation.

Specific up-regulation and down-regulation of immunomodulatory genes in human breast and colorectal cancers. Specific up-regulation and down-regulation.

MDA-468TR-PTEN (with and without 100 ng/ml doxycycline) and MDA-468TR-vector (with dox) were serum starved overnight and the following day treated for.

Activation of mTOR signaling (increased phosphorylated S6 ribosomal protein) and loss of inhibition of IRS-1 in human endometrial carcinomas. Activation.

The AKT–mTOR pathway controls PD-L1 protein expression.

T-cell activation and induction of apoptosis in epithelial cells of oral lesions induced by 4-NQO. T-cell activation and induction of apoptosis in epithelial.

Inhibition of EGFR kinase activity and autophosphorylation by Iressa.

Per1 inhibits growth and induces apoptosis in prostate cancer cell lines. Per1 inhibits growth and induces apoptosis in prostate cancer cell lines. LNCaP,

PTPH1 depends on its catalytic activity to increase ER nuclear accumulation and to enhance breast cancer sensitivity to TAM. A, effects of PTPH1 and PTPH1/DA.

HES1-dependent activation of SRC/STAT3 pathway is mediated by transcription-independent mechanism. HES1-dependent activation of SRC/STAT3 pathway is mediated.

Correlations of the breast cancer hypoxia metagene with Ki67 and the proliferation metagene. Correlations of the breast cancer hypoxia metagene with Ki67.

HMQ1611 inhibited breast tumor growth in mice.

Met is expressed in Her2-overexpressing cell lines and Her2 (+) breast tumors. Met is expressed in Her2-overexpressing cell lines and Her2 (+) breast tumors.

The Ser124 site of Cdc25A is required for Cdc25A degradation in response to I3C induction. The Ser124 site of Cdc25A is required for Cdc25A degradation.

Human cancer immunotherapy strategies targeting B7-H3 A, blockade of B7-H3 with blocking mAbs neutralizes inhibitory signaling in its unidentified receptor(s)

Putative molecular pathways showing how GSK3β regulates the fate of tumor cells (survival, proliferation, or apoptosis) and influences their sensitivity.

Ki-67 and ERα immunostaining in the mammary gland.

Schematic representation of signaling pathways associated with cannabinoid receptor activation induced by its agonists. Schematic representation of signaling.

Establishment of HeLa/rtTAA/TRE-N1-IC cell line.

Anti–PD-1/PD-L1–mediated acquired resistance is dependent on CD38-generated adenosine in the tumor microenvironment. Anti–PD-1/PD-L1–mediated acquired.

Blockade of cell cycle at G2-M phase in Bel-7402 cells treated with IG-105. Blockade of cell cycle at G2-M phase in Bel-7402 cells treated with IG-105.

High nuclear β-catenin levels confer resistance to AKT inhibition and coordinates with increased nuclear FOXO3a to promote metastasis in colon cancer.

Connections between insulin/insulin-like growth factor 1 signaling and metabolic pathways in tumor cells. Connections between insulin/insulin-like growth.

HER2 and PI3K-targeted therapies result in FOXO3a-mediated feedback upregulation of HER3 and IGF1R and provide an escape from PI3K pathway inhibition.

Cell-autonomous mechanisms of resistance to targeted therapies involving the HGF/MET axis. Cell-autonomous mechanisms of resistance to targeted therapies.

Regulation of signaling by wild-type and oncogenic Ras.

Recruitment of CD8+, CD4+, and Foxp3+ cells into oral lesions in response to anti–PD-1 treatment. Recruitment of CD8+, CD4+, and Foxp3+ cells into oral.

Effects of inhibitors of PI3K, MEK1, and GSK-3β on visfatin-induced proliferation in HepG2 cells. Effects of inhibitors of PI3K, MEK1, and GSK-3β on visfatin-induced.

Genomic and proteomic profiling of ovarian cancer cell lines.

I3C reduces the level of Cdc25A protein in breast cancer cells.

Bioinformatic analyses suggest that PI3K/AKT signaling may be a key downstream pathway of tazarotene signaling. Bioinformatic analyses suggest that PI3K/AKT.

CONSORT diagram. a, 5 had a major treatment violation (3 refused and 2 received wrong treatment) but were included in the analyses; b, 4 had a major treatment.

Presentation transcript:

Potential model of HMQ1611 inhibiting breast cancer cell proliferation. Potential model of HMQ1611 inhibiting breast cancer cell proliferation. HMQ1611 regulated ERα expression and membrane-associated E2/ERα pathway, membrane-associated E2/ERα pathway cross-talks with the MAPK pathway, in response to reduced membrane-associated ERα, MAPK activity is suppressed. Meanwhile, inhibition of EGF-induced EGFR phosphorylation by HMQ1611 blocks EGFR activation and its downstream pathways such as MAPKs and PI3K/AKT. Combined blockade of ERα and EGFR pathway leads to reduction of cell proliferation. Yingzhuan Zhan et al. Cancer Prev Res 2012;5:864-873 ©2012 by American Association for Cancer Research